AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

AstraZeneca’s (AZ) Imfinzi (durvalumab ... and gall bladder or ampulla of Vater. Approximately 211,000 new patients are diagnosed with gallbladder and biliary tract cancer each year, about ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

31st Mar 2025 7:05 am RNS Calquence recommended for EU approval in 1L MCL 31st Mar 2025 7:00 am RNS Imfinzi approved in the US for bladder cancer 21st Mar 2025 10:58 am RNS AZN invests $2.5bn in ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The approval of Imfinzi was granted based on results from the pivotal ADRIATIC Phase III trial which demonstrated statistically significant and clinically meaningful results for its dual primary ...

Brain Pathway Links Inflammation to Loss of Motivation, Energy in Advanced Cancer Apr. 10, 2025 — Researchers identified a direct connection between cancer-related inflammation and the loss of ...